Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a 5-year survival rate of 9%. Major obstacles to successful treatment of pancreatic cancer are the immunosuppressive tumor microenvironment (TME) and antigenic complexity or heterogeneity. Programmed death-ligand 1 (PD-L1) is expr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ching-Yao, Fan, Ming Huei, Miao, Carol H., Liao, Yi Jen, Yuan, Ray-Hwang, Liu, Chao Lien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321819/
https://www.ncbi.nlm.nih.gov/pubmed/32637575
http://dx.doi.org/10.1016/j.omto.2020.05.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321819/
https://www.ncbi.nlm.nih.gov/pubmed/32637575
http://dx.doi.org/10.1016/j.omto.2020.05.009

Ejemplares similares